Burlington, Massachusetts, December 19, 2017 — MilliporeSigma, a leader in genome editing, today announced that the Intellectual Property Office of Singapore has issued a “Notice of Eligibility for Grant” for MilliporeSigma’s patent application covering the company’s CRISPR technology used in a genomic-integration method for eukaryotic cells.
"Singapore’s notice of patent allowance for MilliporeSigma’s CRISPR integration technology is yet another reinforcement of our intellectual property,” said Udit Batra, CEO, MilliporeSigma. “We look forward to receiving additional grants for similar patent applications in several other countries as we collaborate with the global scientific community to find new treatments for diseases.”
MilliporeSigma is now licensing these foundational integration patent allowances for applications including basic science research, agricultural biotech and therapeutic use.
This forthcoming, fundamental patent in Singapore, entitled “CRISPR-BASED GENOME MODIFICATION AND REGULATION,” covers chromosomal integration, or cutting of the chromosomal sequence of eukaryotic cells (such as mammalian and plant cells) and insertion of an external or donor DNA sequence into those cells using CRISPR. Scientists can replace a disease-associated mutation with a beneficial or functional sequence, a method important for creating disease models and gene therapy. Additionally, the method can be used to insert transgenes that label endogenous proteins for visual tracking within cells.
CRISPR genome-editing technology, which allows the precise modification of chromosomes in living cells, is advancing treatment options for some of the toughest medical conditions faced today. CRISPR applications are far-ranging — from identifying genes associated with cancer and rare diseases to reversing mutations that cause blindness.
Once issued, the Singapore patent will extend the protection of MilliporeSigma's CRISPR integration technology into Singapore, further strengthening the company's patent portfolio. MilliporeSigma also has patent filings for its insertion CRISPR method in the U.S., Brazil, China, India, Israel, Japan and South Korea. In June 2017, MilliporeSigma was awarded its first CRISPR patent by the Australian patent office. That award was followed by related patent awards by European and Canadian Patent Offices.
With a 12-year history in the genome-editing field, MilliporeSigma was the first company to offer custom biomolecules for genome editing globally (TargeTron™ RNA-guided group II introns and CompoZr™ zinc finger nucleases), driving adoption of these techniques by researchers all over the world. MilliporeSigma was also the first company to manufacture arrayed CRISPR libraries covering the entire human genome, accelerating cures for diseases by allowing scientists to explore more questions about root causes.
MilliporeSigma recognizes the potential benefits of conducting properly defined research with genome editing because of the breakthrough therapeutic potential. Therefore, MilliporeSigma supports research with genome editing under careful consideration of ethical and legal standards. MilliporeSigma’s parent company has established a Bioethics Advisory Panel to provide guidance for research in which its businesses are involved, including research on or using genome editing.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 22,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany generated sales of €16.2 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.